Pablo Lapuerta, the Executive Vice President and Chief Medical Officer of Lexicon Pharmaceuticals, focuses heavily on genetics and drug development. He discusses the messaging that the pharmaceutical industry needs to do in order to help the public understand the extensive processes behind bringing new drugs to market, improvements that could be made in the FDA’s drug approval process, and a novel drug that he and Lexicon have developed to treat Type I diabetes.
Read MoreAlthough genetic testing allowed the Golden State Killer to be found and arrested, it seems to be an egregious breach of information when knowledge of our basic biological building blocks can be analyzed by complete strangers, all without our permission.
Read MoreWhat has made these companies unique is that they also provide information and market directly to the consumer.
Read MoreA discussion of our nation's fixation with fads and diets that are no healthier than their stereotypically unhealthy counterparts in this exclusive interview with Dr. Hyman.
Dr. Hyman is the director of the Cleveland Clinic’s Center for Functional Medicine and a best-selling author.
Read More
